As of November 30, 2024, Hua Ling Pharmaceutical has submitted the latest report on changes in share capital and share movements. The report indicates that the company's statutory/registered share capital remains at 2 billion shares, with a par value of $0.001, totaling $2 million, unchanged from last month. The number of issued shares also stays at 1.056 billion shares, with no additions or reductions occurring. In terms of share options, the number of share options granted under Hua Ling Pharmaceutical's stock option plan following its initial public offering is 52.3576 million, the same as last month, with no exercises, cancellations, or expirations. The company confirms that all securities issuance and the sale or transfer of treasury shares have been authorized by the board of directors and comply with relevant laws and listing rules. Looking forward, Hua Ling Pharmaceutical will continue to monitor its capital structure to ensure compliance with market and legal requirements.

As of November 30, 2024, Hua Ling Pharmaceutical has submitted the latest report on changes in share capital and share movements. The report indicates that the company's statutory/registered share capital remains at 2 billion shares, with a par value of $0.001, totaling $2 million, unchanged from last month. The number of issued shares also stays at 1.056 billion shares, with no additions or reductions occurring. In terms of share options, the number of share options granted under Hua Ling Pharmaceutical's stock option plan following its initial public offering is 52.3576 million, the same as last month, with no exercises, cancellations, or expirations. The company confirms that all securities issuance and the sale or transfer of treasury shares have been authorized by the board of directors and comply with relevant laws and listing rules. Looking forward, Hua Ling Pharmaceutical will continue to monitor its capital structure to ensure compliance with market and legal requirements.